IRLAB Therapeutics: IRL757 brings new flavour - ABG
Summarising an eventful H1'24 Many players in the Parkinson's therapy game... ...but IRLAB has a niche in symptomatic therapy.
ANNONS
Where do we stand today?
IRLAB has made important progress with its pipeline in the last six months. The lead programme mesdopetam passed the FDA end-of-Ph 2 meeting, paving the way for a pivotal Ph 3. Pirepemat's React-PD Ph 2b study reported an update on the patient's baseline characteristics, which enabled a reduction of the study size and the completion of enrolment in Q3'24e, followed by a top-line readout in Q1'25e. The IRL757 programme received funding from MJFF in late '23, financing Ph 1, which started in May'24. Recently IRLAB signed a deal with MSRD, financing IRL757's development through clinical PoC.
